-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Nduc4aVNBcxt8G2zHYXbdNBKtXeyoEy/6ZsbLKlcnDpmJxo0glvL8NR9atSbA69n E+9X6iTcyuXGLRR8uvVJBg== 0001104659-10-030349.txt : 20100524 0001104659-10-030349.hdr.sgml : 20100524 20100524133853 ACCESSION NUMBER: 0001104659-10-030349 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100420 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20100524 DATE AS OF CHANGE: 20100524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVI BIOPHARMA INC CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 10853319 BUSINESS ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425-354-5038 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 8-K/A 1 a10-10280_18ka.htm 8-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

 

(Amendment No. 1)

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 20, 2010

 

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

Oregon

 

001-14895

 

93-0797222

(State or other

 

(Commission File Number)

 

(I.R.S. Employer

jurisdiction of

 

 

 

Identification No.)

incorporation)

 

 

 

 

 

3450 Monte Villa Parkway, Suite 101

Bothell, WA 98021

(Address of principal executive offices)

 

(425) 354-5038

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

EXPLANATORY NOTE

 

On April 22, 2010, AVI BioPharma, Inc. (the “Company”)  filed a Current Report on Form 8-K (“the Original Form 8-K”) to announce, among other things, the acceleration of  the vesting of certain options held by Leslie Hudson Ph.D., the Company’s former Chief Executive Officer and President.  Such acceleration occurred automatically upon Dr. Hudson’s termination without cause in accordance with the Employment Agreement dated February 8, 2008 between the Company and Dr. Hudson (the “Employment Agreement”).

 

The purpose of this Amendment No.1 on Form 8-K/A is to correct the disclosure contained in the Original Form 8-K relating to the number of previously granted options that became fully vested and exercisable as of April 20, 2010.

 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The following table identifies the options held by Dr. Hudson as of April 20, 2010, the vesting of all of which was automatically accelerated upon the effective date of his termination without cause in accordance with Dr. Hudson’s Employment Agreement:

 

Date of Option
Grant

 

Number of
Shares Subject
to the Option

 

Exercise
Price

 

Number of
Options Vested
as of April 20,
2010

 

Number of
Unvested Options
Accelerated as of
April, 20, 2010

 

Termination of
Exercise Period

 

February 8, 2008

 

667,000

 

$

1.09

 

333,500

 

333,500

 

October 20, 2010

 

February 10, 2009

 

350,000

 

$

0.92

 

116,667

 

233,333

 

October 20, 2010

 

February 9, 2010

 

600,000

 

$

1.45

 

0

 

600,000

 

October 20, 2010

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

1,617,000

 

 

 

450,167

 

1,166,833

 

October 20,1010

 

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)           Exhibits

 

Exhibit
No.

 

Description

  3.1

 

First Amendment to the First Restated Bylaws of AVI BioPharma, Inc. (incorporated by reference to Exhibit 3.1 filed with the Original Form 8-K)

 

 

 

10.1

 

Settlement Agreement dated April 20, 2010 among the Company and the Shareholder Group (incorporated by reference to Exhibit 10.1 filed with the Original Form 8-K)

 

 

 

10.2

 

Separation Agreement dated April 20, 2010 between Leslie Hudson and the Company (incorporated by reference to Exhibit 10.2 filed with the Original Form 8-K)

 

2


 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on May 24, 2010.

 

 

AVI BioPharma, Inc.

 

 

 

By:

/s/ J. David Boyle II

 

 

 

 

 

J. David Boyle II

 

 

Interim President and Chief Executive Officer, and
Senior Vice President and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

  3.1

 

First Amendment to the First Restated Bylaws of AVI BioPharma, Inc. (incorporated by reference to Exhibit 3.1 filed with the Original Form 8-K)

 

 

 

10.1

 

Settlement Agreement dated April 20, 2010 among the Company and the Shareholder Group(incorporated by reference to Exhibit 10.1 filed with the Original Form 8-K)

 

 

 

10.2

 

Separation Agreement dated April 20, 2010 between Leslie Hudson and the Company (incorporated by reference to Exhibit 10.2 filed with the Original Form 8-K)

 

4

 

 -----END PRIVACY-ENHANCED MESSAGE-----